As of 14 Oct 2026, SanegeneBio has raised $110M across 1 verified round on record; latest: $110 million Series B, announced 8 Dec 2025.
Innovative RNAi therapeutics for chronic diseases, targeting autoimmune, cardiovascular, obesity, and metabolic diseases for healthcare providers and researchers.
1 source
The lead is described only as “a well-known industry institution” and is not named. Existing shareholders are listed as continuing their support, not as participants in this round.
Published by hand (vcbeathealth.com): "On the evening of December 8, 2025, SANEGENEBIO announced the completion of over $110 million in Series B financing": hand-checked (K, non-US): the page states the company, the equity amount and the day
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-12-08 | not stated | No recent discussion |
1 source [ VERIFIED ] read against 1 source The lead is described only as “a well-known industry institution” and is not named. Existing shareholders are listed as continuing their support, not as participants in this round. Published by hand (vcbeathealth.com): "On the evening of December 8, 2025, SANEGENEBIO announced the completion of over $110 million in Series B financing": hand-checked (K, non-US): the page states the company, the equity amount and the day [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: vcbeathealth.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||